Español
PrintEmail
Decrease (-) Restore Default Increase (+)
In This Section Texas Health Research & Education Institute

Clinical Trials

Disease or Condition   Heart / Cardiac
Title   A Phase 3, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome (Heart/Cardiac)
Description   This study will be looking to see if adding Apixaban (study drug), in addition to a patients' standard care, after an acute coronary syndrome event, is better than standard of care alone in preventing heart attacks, strokes, and other cardiac events.
IRB Number   Pro2030
Inclusion/Notes   INCLUSION:
  • Age 0-18 years.

EXCLUSION:
  • Persistent severe hypertension (SBP = 180 mmHg or DBP = 110 mmHg)

  • Acute pericarditis.

  • Subjects who participated previously in any other study involving apixaban.

  • Severe comorbid condition with life expectancy of = 6 months.

  • Women who are pregnant, breastfeeding, or of childbearing potential and unwilling
    or unable to use an acceptable method of birth control to avoid pregnancy.

  • Prisoners or subjects who are involuntarily incarcerated.
Status   Completed
Location   Texas Health Research & Education Institute
Principal Name    Sukesh Chandrasekar Burjonroppa MD
Contact Name   Tracie Bruton
Phone   (817) 820-4956

Online Tools

Locations

Helpful Info

Links